hotspot -WSS

hotspot

author：focus 2025-09-27 19:50:00 - browse：35553

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Readout Newsletter: Bluebird, CVS, Contineum

WSS

Leading voice in opioid treatment defends methadone clinic system

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Medicare Advantage insurers pressure Biden for bigger payments

Intermittent fasting comes with a heart risk? Not so fast

CRISPR technology availability, affordability needs to be expanded

'Patient friction coefficient' can gauge a clinical trial's patient burden

hotspot

hotspot

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

With Wegovy coverage, Medicare patients may face high costs

Bright Health sells Medicare Advantage business to Molina

Steward Health Care expansion into Malta flopped

After affirmative action ruling, medical educators look to 'holistic review'

Plastic surgeons increase patient psychiatric screenings

Heart attack and stroke risk calculators need revising

What Kate Middleton's cancer revelation might teach the world

DIEP, the 'gold standard' of breast reconstruction, is under threat

Diabetes management: Digital health tools fall short, study says

focus

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Medical devices makers are asking for forgiveness, not permission

This gene therapy has record $4.25 million price. It's saved children.

Methadone treatment changes are coming. Do they go far enough?

App could help diagnose ear infections more accurately — and at home

knowledge

hotspot

knowledge

leisure time